Telemedicine service of Mark Kurtser will be engaged in clinical research

Created by Mark Kurtzer, the Doctis service intends to enter the market for clinical trials of pharmaceuticals. By the end of the year, the platform will become a co-owner of the company, which, in particular, conducts research for the Center.

Subject of the transaction

Telemedicine service "Doctis" received permission from the Federal Antimonopoly Service to acquire a controlling stake in the contract research company "Ipharma", follows from the materials of the department. Skolkovo-registered Digital Medical Operations LLC, a legal entity of Doctis, intends to buy 51% of Ipharma LLC, also based in Skolkovo. The transaction will be closed before the end of this year, the representative of Doctis assured.

Ipharma was established in 2012, is part of the ChemRar group and specializes in the development and registration of pharmaceuticals and clinical trials, in particular in oncology, virology, endocrinology, pulmonology, neurology, and psychiatry. In 2020, this company, according to its own data, conducted clinical trials of candidate drugs for the treatment and prevention of COVID-19 , including the Sputnik V vaccine in the Republic of Belarus. This year, Ipharma received a contract from the NITsEM named after N.F. Gamaleya, the developer of the anti-covid vaccine, to conduct a clinical trial of the effectiveness of the tuberculosis vaccine GamTBvac. The contract value is 54.3 million rubles.

The revenue of Ipharma LLC in 2020 according to RAS amounted to 978.7 million rubles, net profit - 360.3 million rubles.

The Ministry of Health recommended treating COVID-19 at home using telemedicine Society